Loading company
Alzamend Neuro, Inc.
ALZN · Nasdaq · ·
$1.83+4.9%Sep 29 close
- 1M
- +10.2%
- 6M
- +72.6%
- 1Y
- -23.1%
- 5Y
- -100.0%
ALZN · Nasdaq · ·
$1.83+4.9%Sep 29 close
The quarter ending July 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toJul 31, 2026 | 3 months toJul 31, 2025 | Change |
|---|---|---|---|
| Profit | -$3M | -$2.7M | -12.00% |
| Profit per share | -$0.68 | -$1.28 | +46.88% |
| Free Cash Flow | -$898.7K | -$1.4M | +37.01% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Alzamend Neuro, Inc. has no earnings call transcript available.
“The successful completion of this Financing, months ahead of schedule, reflects confidence in our mission and strong belief in our vision,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Alzamend Neuro, Inc.’s Item 2.02 8-K filed July 23, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.